AUROPHARMA - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.4
| Stock Code | AUROPHARMA | Market Cap | 79,915 Cr. | Current Price | 1,376 ₹ | High / Low | 1,460 ₹ |
| Stock P/E | 37.3 | Book Value | 369 ₹ | Dividend Yield | 0.29 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,317 ₹ | DMA 200 | 1,220 ₹ |
| Chg in FII Hold | 1.29 % | Chg in DII Hold | -1.84 % | PAT Qtr | 595 Cr. | PAT Prev Qtr | 581 Cr. |
| RSI | 54.4 | MACD | 29.6 | Volume | 8,06,168 | Avg Vol 1Wk | 10,15,573 |
| Low price | 1,016 ₹ | High price | 1,460 ₹ | PEG Ratio | 8.73 | Debt to equity | 0.21 |
| 52w Index | 81.1 % | Qtr Profit Var | 26.0 % | EPS | 36.7 ₹ | Industry PE | 30.2 |
Analysis: AUROPHARMA trades at ₹1,376, above both 50 DMA (₹1,317) and 200 DMA (₹1,220), showing strong technical support. RSI at 54.4 is neutral, while MACD is positive, suggesting bullish momentum. Fundamentals are moderate with ROCE at 10.8% and ROE at 8.65%. Valuation is slightly above industry average (P/E 37.3 vs 30.2). Quarterly profit improved (+26%), supporting sentiment. PEG ratio of 8.73 indicates expensive growth expectations, but balance sheet remains stable with debt-to-equity at 0.21.
Optimal Entry: Entry is favorable near ₹1,330–1,350, closer to support levels.
Exit Strategy: If already holding, consider exiting near ₹1,420–1,450 unless momentum continues strongly.
✅ Positive
- Quarterly profit growth (+26%) boosts investor confidence.
- Trading above both 50 DMA and 200 DMA, showing bullish trend.
- FII holdings increased (+1.29%), showing foreign investor confidence.
⚠️ Limitation
- Valuation above peers (P/E 37.3 vs industry 30.2).
- Moderate ROCE (10.8%) and ROE (8.65%), not very strong.
- PEG ratio of 8.73 indicates expensive growth expectations.
📉 Company Negative News
- DII holdings decreased (-1.84%), showing reduced domestic institutional interest.
- Profitability ratios remain moderate compared to industry leaders.
📈 Company Positive News
- Quarterly profit improved to ₹595 Cr from ₹581 Cr.
- EPS of ₹36.7 supports earnings strength.
- Strong 52-week performance (+81.1%).
🏭 Industry
- Industry P/E is 30.2, lower than AUROPHARMA’s 37.3.
- Pharma sector shows steady demand but valuations are more moderate compared to AUROPHARMA.
📝 Conclusion
AUROPHARMA is a moderately strong candidate for swing trading with bullish technicals and improving profits. Entry near ₹1,330–1,350 offers better risk-reward. Holders can target exits around ₹1,420–1,450 unless momentum continues. Overvaluation and moderate fundamentals warrant caution, but short-term trend remains positive.